
Gray whales are dying off the Pacific Coast again, and scientists aren't sure why.
Gray whales are dying in large numbers, again.
At least 70 whales have perished since the start of the year in the shallow, protected lagoons of Mexico's Baja California peninsula where the animals have congregated for eons to calf, nurse and breed, said Steven Swartz, a marine scientist who has studied gray whales since 1977. And only five mother-calf pairs were identified in Laguna San Ignacio, where most of the wintering whales tend to congregate, Swartz said.
That's the lowest number of mother-calf pairs ever observed in the lagoon, according to annual reports from Gray Whale Research in Mexico, an international team of researchers — co-founded by Swartz — that has been observing gray whales in Laguna San Ignacio since the late 1970s.
The whales are now headed north. In just the last two weeks, three gray whales have died in San Francisco Bay, one of which was described by veterinarians and pathologists at the Marine Mammal Center in Sausalito as skinny and malnutritioned. Evaluations on the two other deaths are still being conducted.
Alisa Schulman-Janiger, who has led the Los Angeles chapter of the American Cetacean Society's gray whale census at Rancho Palos Verdes since 1979, said the number of whales she and her volunteers have observed migrating north this spring and swimming south this past winter is the lowest on record.
'We didn't see a single southbound calf, which has never happened in 40 years,' she said.
Schulman-Janiger and other researchers aren't sure why the whales are dying, although she and others believe it could be from lack of food based on the depleted conditions in which some of the whales have been found.
Eastern North Pacific gray whales cruise the Pacific coastline every year as they migrate 6,000 miles north from the Baja peninsula to their summer feeding grounds in Arctic and sub-Arctic regions. There, the leviathans gorge themselves on small crustaceans and amphipods that live in the muddy sediment of the Bering, Chukchi and Beaufort seas, before they head back south to loll, cavort and mingle in balmy Mexican waters.
The animals migrate through a gantlet of perils as they navigate some of the world's most heavily shipped regions, maneuver through discarded fishing lines and gear, dodge pods of killer whales waiting to tear apart defenseless calves, and swim through waters polluted with microplastics, toxic chemicals and poisonous algae.
Most of the time, the bulk of them make the journey just fine.
But in 2019, large numbers of the whales began to die.
Starting that spring, biologists at the Laguna San Ignacio research station recorded roughly 80 dead whales in Mexican waters, and just 41 mother-calf pairs in the lagoon. They also noticed — using photographs and drone imagery — that roughly a quarter of the animals were 'skinny.'
'You can see it in photographs,' said Schulman-Janiger, who described skinny whales as looking like they had necks because a thick fat pad that typically covers the area behind the skull is gone. 'And you can see their scapulae,' she said, referring to the animals' shoulder blades.
'You shouldn't see a whale's shoulder blades,' she said.
Then, as the hungry whales migrated north in 2019, large numbers began stranding on the beaches of California, Oregon, Washington and Alaska. By the end of that year, researchers had documented 216 dead whales on the beaches and near shore waters of the North American Pacific coastline.
A federal investigation by the National Oceanic and Atmospheric Administration into what is known as an unexplained mortality event was launched in 2019. The investigation allowed for scientists across multiple disciplines and institutions to gather and share knowledge to determine the cause of the die-off.
The cause of the deaths was never definitively established, and the investigation was closed in 2023 as the number of strandings fell into a range considered normal. Many researchers concluded a change in Arctic and sub-Arctic food availability (via massive changes in climate) was the driving factor. Their assessment was supported by the observations of malnutrition and skinniness in the whales and similar events and observations in other Arctic animals, including birds, seals, crabs and fish.
They also noticed that many of the whales had started feeding in areas — such as San Francisco Bay and the Los Angeles and Long Beach harbors — where such behaviors had never before been seen.
In the last two weeks, several gray whales have been observed in San Francisco Bay, including a near record high of nine on a single day. Reports of feeding behaviors had also been made, including off the city of Pacifica.
Asked whether the researchers at NOAA are noting these concerning observations and anticipating the possibility of another die-off, Michael Milstein, an agency spokesman, said the number of strandings along the Pacific coast is still low — just seven in California and one in Washington. The annual average is about 35.
He said it was too early in the whales' northward journey to know for sure.
John Calambokidis, senior research biologist and co-founder of the Cascadia Research Collective, a marine mammal research center based in Olympia, Wash., agreed with Milstein: 'We are just entering our main period of strandings (April to June) so a little early to draw any conclusions.'
And despite Schulman-Janiger's concerns, she too said it is early — and that La Niña ocean conditions may be partly to blame for the low number of animals observed thus far.
She said reports from Mexico indicate many gray whales migrated farther south than they typically do, and have been seen swimming around the Gulf of California — off the coasts of Loreto, Cabo San Lucas and Puerto Vallarta.
She said that is good news if the low counts are due to the whales just being late. But worrisome if already food-stressed whales are having to tack on an additional 800 miles to their journey.
'It's a very weird year for gray whales, and a concerning year given their body condition, the strandings and the very low calf estimates,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Miami Herald
3 hours ago
- Miami Herald
10-foot-long predator — with toxic flesh — is first-of-its-kind catch off Mexico
Off the coast of Veracruz, Mexico, fishermen attached hunks of bonito fish to a longline and dropped it in the water. The nearly 400-foot line drug through the water until something heavy chomped down on the bait and was reeled to the surface. The fishermen recorded a video of the creature on the end of the line as it approached the boat on the July day in 2024, possibly not realizing the significance of the catch. The hook was caught in the mouth of a bluntnose sixgill shark — the first ever confirmed catch 'for Mexican waters of the Gulf of Mexico and the Caribbean Sea.' The shark was brought to shore to be weighed and measured, according to a study published June 6 in the peer-reviewed journal Acta Ichthyologica et Piscatoria. The nearly 10-foot-long shark has a 'robust body' and a 'large and broad head,' researchers said. The shark's 'big mouth' holds 'six rows of large, serrated comb-shaped teeth on each side of the lower jaw.' The shark has a 'prominent tapetum lucidum,' or reflective layer in the eye, that makes their eyes appear 'fluorescent greenish' while alive. The shark was a sexually mature male, likely at the peak of its size, researchers said. Bluntnose sixgill sharks, or Hexanchus griseus, can be found globally, but in patches of ocean instead of widely distributed, according to the study. The first record of the shark in the Gulf of Mexico was in 1962 when a 14-foot female was caught off the coast of Alabama, according to the study. A 10-foot male bluntnose sixgill shark was caught off the coast of Texas in 1984. This record, however, confirms the species's distribution to the southwest region of the Gulf. 'Local fishermen have reported capturing the species on several occasions, however the specimens were released since the flesh is bland and not well appreciated due to its consistency,' according to the study. 'It also has a large amount of fat which is considered toxic. For this reason, species of the genera Hexanchus and Heptranchias have been dubbed milk sharks by local fishermen.' The shark's flesh has an incredibly high concentration of oil, leading to the meat being considered ichthyosarcotoxic, and not safe to eat, according to the study. This means that when the sharks are caught it is typically incidental and they are not specifically targeted in any commercial operations, researchers said. The sharks are usually found below 300 feet, though juveniles swim closer to coastal areas, according to the study. The shark was caught 12 miles north of the community of Salinas Roca Partida. The Gulf of Mexico was renamed as the Gulf of America by executive order on Jan. 20 by President Donald Trump. This change is not recognized outside the United States. The research team includes Luis Fernando Del Moral-Flores, Sergio Alejandro Lozano-Quiroz, Viridiana R. Escartín-Alpizar, Eduardo García-Mercado and Rolando Hernández-Ortiz.
Yahoo
4 hours ago
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified individual.